EVO
Evotec SE
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
1.93
▼ 0.03 (1.53%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.98
Prev close
1.96
Day high
1.95
Day low
1.92
Volume
40.87K
Market cap
$685.90M
P/E (TTM)
—
52W range
1.89 – 4.27
Day trading desk
Gap from prior close
+0.90%
Prior close 1.96
VWAP
1.94
-0.48% from price
Relative volume
0.76×
Normal
Session range
3.27%
1.91 – 1.98
Position in range
24%
Near session low
ATR (14D)
0.08
4.07% of price
Prior day high
1.96
PDH
Prior day low
1.92
PDL
Bid / ask spread
—
Quote not published
Session volume
40.90K
Avg 53.58K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.53%
-0.2%
1M
-2.53%
-6.3%
3M
-35.45%
-38.5%
6M
-45.33%
-56.4%
YTD
-37.34%
-49.6%
1Y
-45.94%
-65.9%
3Y
-82.95%
-157.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on EVO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
17.77K
Total on file
Fundamentals
Market cap$685.90M
Enterprise value$696.10M
Revenue (TTM)$717.28M
Gross profit$60.71M
EBITDA$-73.18M
Net income$-197.05M
EPS (TTM)$-0.65
Free cash flow$-80.99M
Total cash$465.59M
Total debt$475.87M
Book value / share$2.19
Shares outstanding355.39M
Float270.77M
Short % of float0.01%
Dividend yield—
Beta (5Y)1.26
Valuation & profitability ratios
Trailing P/E—
Forward P/E-10.16
PEG ratio1.42
Price / sales—
Price / book0.88
EV / revenue0.97
EV / EBITDA-9.51
Gross margin8.46%
Operating margin-62.26%
Profit margin-27.47%
Return on equity-26.07%
Return on assets-5.39%
Debt / equity71.50
Current ratio2.33
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $788.37M | $796.97M | $781.43M | $751.45M | -1.1% |
| Operating revenue | $788.37M | $796.97M | $781.43M | $751.45M | -1.1% |
| Cost of revenue | $674.15M | $682.09M | $606.38M | $577.38M | -1.2% |
| Gross profit | $114.22M | $114.88M | $175.05M | $174.06M | -0.6% |
| Research & development | $37.51M | $50.86M | $68.53M | $76.64M | -26.2% |
| Selling, general & admin | $175.97M | $188.20M | $169.61M | $156.19M | -6.5% |
| Total operating expense | $170.04M | $193.80M | $201.68M | $153.22M | -12.3% |
| Operating income | -$55.82M | -$78.92M | -$26.63M | $20.85M | +29.3% |
| Net interest income | -$10.02M | -$9.26M | -$2.48M | -$4.81M | -8.1% |
| Pre-tax income | -$86.77M | -$193.98M | -$80.59M | -$153.96M | +55.3% |
| Tax provision | $16.75M | $2.10M | $3.32M | $21.70M | +696.9% |
| Net income | -$103.52M | -$196.08M | -$83.91M | -$175.66M | +47.2% |
| Net income to common | -$103.52M | -$196.08M | -$83.91M | -$175.66M | +47.2% |
| Basic EPS | -0.29 | -0.56 | -0.24 | -0.50 | +47.7% |
| Diluted EPS | -0.29 | -0.56 | -0.24 | -0.50 | +47.7% |
| EBIT | -$72.32M | -$182.28M | -$68.85M | -$140.81M | +60.3% |
| EBITDA | $27.15M | -$80.66M | $24.13M | -$57.61M | +133.7% |
| Basic shares | 355.16M | 354.59M | 353.83M | 353.35M | +0.2% |
| Diluted shares | 355.16M | 354.59M | 353.83M | 353.35M | +0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $401.79M | $293.46M | $510.91M | $400.70M | +36.9% |
| Cash & short-term investments | $463.01M | $367.68M | $604.11M | $707.31M | +25.9% |
| Accounts receivable | $135.96M | $116.32M | $98.40M | $171.80M | +16.9% |
| Inventory | $29.32M | $31.12M | $30.89M | $29.82M | -5.8% |
| Total current assets | $762.95M | $681.96M | $903.16M | $1.07B | +11.9% |
| Property, plant & equipment | $554.63M | $823.94M | $806.56M | $650.20M | -32.7% |
| Goodwill & intangibles | $303.94M | $309.30M | $291.09M | $298.64M | -1.7% |
| Total assets | $1.71B | $1.91B | $2.25B | $2.26B | -10.4% |
| Total current liabilities | $368.07M | $344.58M | $464.57M | $337.71M | +6.8% |
| Current debt | $81.50M | $50.80M | $149.10M | $1.56M | +60.4% |
| Long-term debt | $344.01M | $392.74M | $477.11M | $328.30M | -12.4% |
| Total debt | $447.69M | $443.54M | $626.21M | $506.67M | +0.9% |
| Total liabilities | $900.24M | $959.98M | $1.13B | $1.07B | -6.2% |
| Retained earnings | -$775.89M | -$672.37M | -$476.29M | -$392.38M | -15.4% |
| Shareholder equity | $813.70M | $952.52M | $1.12B | $1.19B | -14.6% |
| Working capital | $394.87M | $337.38M | $438.59M | $735.97M | +17.0% |
| Net tangible assets | $509.77M | $643.23M | $828.82M | $888.55M | -20.7% |
| Shares issued | 177.78M | 177.72M | 177.44M | 177.20M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$103.52M | -$196.08M | -$83.91M | -$175.66M | +47.2% |
| Depreciation & amortisation | $99.48M | $101.62M | $92.98M | $83.20M | -2.1% |
| Stock-based compensation | $3.78M | $5.04M | $9.63M | $9.92M | -25.0% |
| Change in working capital | -$60.80M | -$68.21M | -$9.94M | $105.28M | +10.9% |
| Operating cash flow | -$9.18M | $18.22M | $36.44M | $205.81M | -150.4% |
| Capital expenditure | -$82.62M | -$132.24M | -$216.00M | -$181.35M | +37.5% |
| Investing cash flow | $171.59M | -$71.19M | -$13.29M | -$412.80M | +341.0% |
| Share buybacks | -$1.55M | $0 | $0 | — | — |
| Dividends paid | $0 | $0 | $0 | $0 | — |
| Financing cash flow | -$37.63M | -$161.42M | $71.96M | -$58.15M | +76.7% |
| Free cash flow | -$91.80M | -$114.02M | -$179.56M | $24.46M | +19.5% |
| End cash position | $418.52M | $306.39M | $510.91M | $415.15M | +36.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $156.64M | $253.27M | $163.89M | $171.24M | $199.98M | -38.2% |
| Operating revenue | $156.64M | $253.27M | $163.89M | $171.24M | $199.98M | -38.2% |
| Cost of revenue | $158.21M | $174.81M | $163.95M | $162.64M | $166.74M | -9.5% |
| Gross profit | -$1.57M | $78.46M | -$62.00K | $8.59M | $33.24M | -102.0% |
| Research & development | $10.08M | $9.83M | $8.71M | $8.21M | $14.93M | +2.6% |
| Selling, general & admin | $43.79M | $44.35M | $42.31M | $41.61M | $49.54M | -1.3% |
| Total operating expense | $44.85M | $41.26M | $44.55M | $37.19M | $53.05M | +8.7% |
| Operating income | -$46.42M | $37.21M | -$44.61M | -$28.60M | -$19.82M | -224.8% |
| Net interest income | -$790.00K | -$2.60M | -$1.44M | -$4.79M | -$1.19M | +69.6% |
| Pre-tax income | -$122.18M | $29.46M | -$42.96M | -$43.42M | -$29.85M | -514.7% |
| Tax provision | -$244.00K | $14.84M | $127.00K | $59.00K | $1.73M | -101.6% |
| Net income | -$121.94M | $14.62M | -$43.09M | -$43.48M | -$31.58M | -933.8% |
| Net income to common | -$121.94M | $14.62M | -$43.09M | -$43.48M | -$31.58M | -933.8% |
| Basic EPS | -0.34 | — | -0.12 | -0.12 | -0.09 | — |
| Diluted EPS | -0.35 | — | -0.12 | -0.12 | -0.09 | — |
| EBIT | -$119.60M | $33.22M | -$40.68M | -$37.42M | -$27.44M | -460.0% |
| EBITDA | -$119.60M | $33.22M | -$40.68M | -$37.42M | -$27.44M | -460.0% |
| Basic shares | 355.12M | — | 355.34M | 355.19M | 355.05M | — |
| Diluted shares | 355.12M | — | 355.34M | 355.19M | 355.05M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $387.91M | $401.79M | $174.04M | $267.82M | $285.38M | — | -3.5% |
| Cash & short-term investments | $463.78M | $463.01M | $242.79M | $356.40M | $378.71M | — | +0.2% |
| Accounts receivable | $98.26M | $135.96M | $103.77M | $85.17M | $167.28M | — | -27.7% |
| Inventory | $32.98M | $29.32M | $31.18M | $34.56M | $33.51M | — | +12.5% |
| Total current assets | $711.28M | $762.95M | $793.12M | $604.45M | $723.88M | — | -6.8% |
| Property, plant & equipment | $530.84M | $554.63M | $565.23M | $782.70M | $808.77M | — | -4.3% |
| Goodwill & intangibles | $305.41M | $303.94M | $300.56M | $304.29M | $308.28M | — | +0.5% |
| Total assets | $1.64B | $1.71B | $1.77B | $1.81B | $1.94B | — | -4.3% |
| Total current liabilities | $423.37M | $368.07M | $374.47M | $383.19M | $356.92M | — | +15.0% |
| Current debt | — | $81.50M | — | — | — | $50.80M | — |
| Long-term debt | $298.85M | $344.01M | — | — | — | $392.74M | -13.1% |
| Total debt | $387.46M | $447.69M | $96.87M | $106.86M | $60.92M | — | -13.5% |
| Total liabilities | $940.19M | $900.24M | $972.56M | $962.47M | $1.03B | — | +4.4% |
| Retained earnings | -$897.82M | -$775.89M | -$790.51M | -$747.42M | -$703.95M | — | -15.7% |
| Shareholder equity | $699.62M | $813.70M | $800.14M | $845.79M | $912.14M | — | -14.0% |
| Working capital | $287.90M | $394.87M | $418.65M | $221.26M | $366.96M | — | -27.1% |
| Net tangible assets | $394.21M | $509.77M | $499.58M | $541.49M | $603.86M | — | -22.7% |
| Shares issued | 177.59M | 177.78M | 177.77M | 177.76M | 177.93M | — | -0.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$121.94M | $14.62M | -$43.09M | -$43.48M | -$31.58M | -933.8% |
| Change in working capital | $71.49M | $6.27M | -$96.20M | $62.32M | -$33.20M | +1,039.6% |
| Operating cash flow | -$3.92M | $63.63M | -$67.56M | $26.56M | -$31.81M | -106.2% |
| Capital expenditure | -$10.79M | -$15.52M | -$21.40M | -$23.86M | -$21.84M | +30.5% |
| Investing cash flow | -$12.43M | $222.38M | -$7.24M | -$21.94M | -$21.61M | -105.6% |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | -$19.09M | -$46.23M | -$12.13M | -$14.70M | $35.43M | +58.7% |
| Free cash flow | -$14.70M | $48.11M | -$88.96M | $2.70M | -$53.65M | -130.6% |
| End cash position | $387.91M | $418.52M | $179.27M | $267.82M | $285.38M | -7.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.04 | -0.13 | -225.0% |
| Mar 2026 | -0.18 | -0.35 | -97.1% |
| Dec 2025 | 0.07 | 0.05 | -35.7% |
| Sep 2025 | -0.17 | -0.12 | +28.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.31 | 2 | $135.69M | -17.2% |
| Next quarter | -0.29 | 2 | $153.86M | -39.3% |
| Current year | -1.54 | 2 | $599.67M | -23.9% |
| Next year | -0.38 | 2 | $719.19M | +19.9% |
Analyst targets & ownership
Mean target$3.86
High target$6.94
Low target$2.02
Implied upside100.07%
Analyst count4
ConsensusBUY
Strong buy / Buy1 / 1
Hold1
Sell / Strong sell0 / 1
Held by insiders0.01%
Held by institutions0.81%
Institutions holding35
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.01
-3.93% from price
SMA 20
1.98
-2.43% from price
SMA 50
2.30
-16.04% from price
SMA 100
2.62
-26.20% from price
SMA 200
2.90
-33.42% from price
EMA 12
1.98
-2.68% from price
EMA 26
2.07
-6.62% from price
EMA 50
2.25
-14.05% from price
RSI (14)
39.2
Neutral
MACD (12,26,9)
-0.08
Hist 0.02
ATR (14)
0.08
4.07% of price
Realised vol 30D
66.1%
Annualised
Bollinger upper
2.12
20, 2σ
Bollinger lower
1.84
20, 2σ
50 / 200 cross
Death
2.30 vs 2.90
Trend bias
Below 200
-33.42%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.52
More volatile than market
Correlation to SPY
0.36
Loosely linked
Realised vol 30D
66.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-54.0%
Peak to trough
Max drawdown 5Y
-92.8%
Peak to trough
ATR 14
0.08
4.07% of price
Beta (reported)
1.26
5Y monthly, from filing
Short interest
Shares short
47.63K
Prior 53.01K
Change vs prior
-10.2%
Shorts covering
% of float
0.01%
Normal
% of shares out
0.01%
Against total outstanding
Days to cover
0.8
Liquid
Float
270.77M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 7, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 23, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 25, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 31, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 12, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 23, 23 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Jun 16, 23 | B of A Securities | DOWNGRADE | Buy | Neutral |
| Jun 8, 23 | Citigroup | UPGRADE | Neutral | Buy |
| Apr 4, 23 | Morgan Stanley | UPGRADE | Underweight | Equal-Weight |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split4:1
Split dateOct 20, 2021
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-13
Corporate Changes & Voting Matters
6-K · 2026-07-14
Corporate Changes & Voting Matters
6-K · 2026-06-30
Corporate Changes & Voting Matters
6-K · 2026-06-17
Corporate Changes & Voting Matters
6-K · 2026-05-06
Corporate Changes & Voting Matters
6-K · 2026-04-24
Periodic Financial Reports
20-F · 2026-04-08
Corporate Changes & Voting Matters
6-K · 2026-04-07
Headlines
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention
Simply Wall St. · 13d ago
Evotec and Odyssey collaborate on AI-enabled R&D
Pharmaceutical Technology · 16d ago
Evotec, Odyssey Therapeutics Partner to Develop Autoimmune, Inflammatory Disease Treatments
MT Newswires · 17d ago
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
PR Newswire · 17d ago
Niagen Bioscience, Evotec to Advance Preclinical Development of NB4168
MT Newswires · 20d ago
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Business Wire · 20d ago
Navan Selected by Evotec for Global Travel, Expense Management
MT Newswires · 31d ago
Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management
Business Wire · 31d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.